Civica, BCBS To Make New Insulin Biosimilar Available Come January

By Gabrielle Wanneh / October 16, 2025 at 5:12 PM

Non-profit drug company Civica is launching a long-acting insulin biosimilar available at the lowest price in the market in the United States beginning next year.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.